This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Development of Magnetic Resonance (MR) Simulation for Treatment Planning

This study has been completed.
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta Identifier:
First received: April 11, 2006
Last updated: February 24, 2016
Last verified: January 2012

Retrospectively have access to MR images of patients to develop software that:

  1. segment images
  2. convert MR values to electron density and then
  3. entered into a dose calculation system

The project involves software development of data that is already available. No intervention is made at this point.


Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Development of MR Simulation for Treatment Planning

Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 10
Study Start Date: September 2005
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patient with conform histological diagnosis of glioblastoma multiforme signed the consent forms and were willing to go for curative radiation treatment with temozolomide

Inclusion Criteria:

  • Subject 18 years of age and older
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00314496

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Principal Investigator: Gino Fallone, PhD AHS Cancer Control Alberta
  More Information

Responsible Party: AHS Cancer Control Alberta Identifier: NCT00314496     History of Changes
Other Study ID Numbers: EX-0004
Study First Received: April 11, 2006
Last Updated: February 24, 2016 processed this record on August 17, 2017